| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002072900 |
| P356 | DOI | 10.1007/S12022-014-9335-6 |
| P698 | PubMed publication ID | 25252622 |
| P50 | author | Luisella Righi | Q60732082 |
| Marco Volante | Q85849462 | ||
| Mauro Papotti | Q88962015 | ||
| Simona Vatrano | Q114516496 | ||
| Ida Rapa | Q115137302 | ||
| P2093 | author name string | Giuseppe Pelosi | |
| P2860 | cites work | Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives. | Q33767627 |
| Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology | Q33949939 | ||
| Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids | Q34045543 | ||
| Advances in neuroendocrine lung tumors | Q34143347 | ||
| Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy | Q63383652 | ||
| Atypical carcinoid tumors of the lung | Q70440763 | ||
| Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and Kl-67-labeling study | Q71941342 | ||
| The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung | Q73069375 | ||
| MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma | Q73595299 | ||
| Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid | Q77101570 | ||
| 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma | Q78859035 | ||
| ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival | Q82659735 | ||
| Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung | Q84208688 | ||
| Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas | Q84561565 | ||
| TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies | Q84700490 | ||
| Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q85009890 | ||
| Neuroendocrine carcinomas of the lung: a critical analysis | Q34920930 | ||
| O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors | Q35001754 | ||
| Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. | Q35167949 | ||
| Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score | Q35972107 | ||
| Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients | Q36006406 | ||
| Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. | Q36230888 | ||
| Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer | Q36568988 | ||
| Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases | Q36649399 | ||
| The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer | Q37315250 | ||
| Neuroendocrine tumors of the lung: an update | Q37806228 | ||
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study | Q37961390 | ||
| Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas | Q37972983 | ||
| Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. | Q38009559 | ||
| Focus on treatment of lung carcinoid tumor | Q38159687 | ||
| Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice | Q38187221 | ||
| Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors | Q38207553 | ||
| mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. | Q39154831 | ||
| CD44 and OTP are strong prognostic markers for pulmonary carcinoids | Q39187969 | ||
| TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma | Q39212064 | ||
| Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors | Q39279767 | ||
| Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway | Q39388106 | ||
| Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung | Q39590292 | ||
| Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. | Q39659401 | ||
| ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization | Q42435605 | ||
| Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung | Q42651022 | ||
| Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. | Q43080122 | ||
| Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. | Q43275679 | ||
| MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. | Q43830266 | ||
| hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors | Q43995734 | ||
| Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors | Q45072953 | ||
| Grading the neuroendocrine tumors of the lung: an evidence-based proposal. | Q45690367 | ||
| Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma | Q45800635 | ||
| Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. | Q46354494 | ||
| Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study | Q46561878 | ||
| Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors | Q46606606 | ||
| Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung | Q46825169 | ||
| Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy | Q47386241 | ||
| An exploration of pathways involved in lung carcinoid progression using gene expression profiling. | Q50728982 | ||
| Neuroendocrine neoplasms of the lung: a prognostic spectrum. | Q53642652 | ||
| P433 | issue | 4 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 371-377 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | Endocrine Pathology | Q15757049 |
| P1476 | title | Therapeutic biomarkers in lung neuroendocrine neoplasia | |
| P478 | volume | 25 |
| Q37437375 | Bi-directional roles of IRF-1 on autophagy diminish its prognostic value as compared with Ki67 in liver transplantation for hepatocellular carcinoma |
| Q47965331 | Cyto-histology in NET: what is necessary today and what is the future? |
| Q55141745 | Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. |
| Q40395607 | Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied |
| Q91624644 | Systemic treatment for lung carcinoids: from bench to bedside |
| Q38441413 | The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors |
Search more.